Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

Item

http://www.wikidata.org/entity/Q38018674

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

@en

type

Item

label

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

@en

prefLabel

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

@en

P1476

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes

@en

P2093

Rashi Joshi

http://www.w3.org/2001/XMLSchema#string

Stan Heptinstall

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.

P304

257-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECP.12.17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dr Yanushi Dullewe Wijeyeratne

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225372979

http://www.w3.org/2001/XMLSchema#string

P698

22697589

http://www.w3.org/2001/XMLSchema#string